Response to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degeneration

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 45, Issue 5, 2014, Pages 394-397

  Eadie, James A ^a,b   Gottlieb, Justin L ^a   Ip, Michael S ^a   Blodi, Barbara A ^a   Danis, Ronald P ^a   Chandra, Suresh R ^a   Nork, T Michael ^a   Altaweel, Michael M ^a   Stern Hogan, Brendan S ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Retina Vitreous Consultants   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OPTICAL COHERENCE TOMOGRAPHY; RETINA EXUDATE; RETINAL THICKNESS; SUBRETINAL FLUID; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL ACUITY CHART; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; DRUG SUBSTITUTION; INTRAVITREAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84911425292     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20140909-03     Document Type: Article

References (11)

1. Rosenfeld P, Brown D, Heier J, et al. Ranubizumab for neovascular age-related macular degeneration. N Eng J Med. 2006;355(14):1419-1431.
2. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIb study to evaluate the safety of ranubizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116(9):1731-1739.
3. Brown DM, Kaiser PK, Michels M, et al. Ranubizumab versus verteporforin photodynamic therapy for neovascular age-related macular degeneration. Twp year results from the ANCHOR study. Ophthalmology. 2009;116(1):57-65 e5.
4. Martin D, Maguire M, Fine S, et al. Ranibizumab and Bevacizumab for treatment of Neovascular Age-related Macular Degeneration Two Year Results. Ophthalmology. 2012;119(7):1388-1398.
5. Papadopoulos N, Martin J, Run Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171-185.
6. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci. U S A. 2002;99(17):11393-11398.
7. Heier J, Brown D, Chong V, et al. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-Related Macular Degeneration. Ophthalmology. 2013;120(1):209-210.
8. ASRS PAT Survey 2012. http://www.asrs.org/asrs-community/patsurvey
9. Cho H, Shah C, Weber M, Heier J. Aflibercept for exudative AMD with persistent fluid on ranubizumab and/or bevaczumab. Br J Ophthalmol. 2013;97(8):1032-1035.
10. Martin D, Maguire M, Ying G, et al. Ranubizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
11. Bakall B, Folk J, Boldt H, et al. Aflibercept Therapy for Exudative Age-related Macular Degeneration Resistant to Bevacizumab and Ranubizumab. Am J Ophthalmol. 2013;156(1):15-22.